k14 Search Results


90
ATCC human krt14
a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of <t>KRT14</t> and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.
Human Krt14, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human krt14/product/ATCC
Average 90 stars, based on 1 article reviews
human krt14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

94
Developmental Studies Hybridoma Bank kv1 2
a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of <t>KRT14</t> and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.
Kv1 2, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/kv1 2/product/Developmental Studies Hybridoma Bank
Average 94 stars, based on 1 article reviews
kv1 2 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

97
Proteintech anti keratin 14
a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of <t>KRT14</t> and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.
Anti Keratin 14, supplied by Proteintech, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti keratin 14/product/Proteintech
Average 97 stars, based on 1 article reviews
anti keratin 14 - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

93
Biorbyt histone h3 acetyl k14
a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of <t>KRT14</t> and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.
Histone H3 Acetyl K14, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/histone h3 acetyl k14/product/Biorbyt
Average 93 stars, based on 1 article reviews
histone h3 acetyl k14 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Mini-Circuits low pass filters
a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of <t>KRT14</t> and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.
Low Pass Filters, supplied by Mini-Circuits, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low pass filters/product/Mini-Circuits
Average 93 stars, based on 1 article reviews
low pass filters - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Boster Bio k14
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
K14, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k14/product/Boster Bio
Average 93 stars, based on 1 article reviews
k14 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cytokeratin 14 fitc
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
Anti Cytokeratin 14 Fitc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cytokeratin 14 fitc/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cytokeratin 14 fitc - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

k14  (Biorbyt)
93
Biorbyt k14
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
K14, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k14/product/Biorbyt
Average 93 stars, based on 1 article reviews
k14 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

94
Miltenyi Biotec anti cytokeratin 14 reafinitytm
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
Anti Cytokeratin 14 Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cytokeratin 14 reafinitytm/product/Miltenyi Biotec
Average 94 stars, based on 1 article reviews
anti cytokeratin 14 reafinitytm - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier

85
Santa Cruz Biotechnology k14 antibody
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
K14 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k14 antibody/product/Santa Cruz Biotechnology
Average 85 stars, based on 1 article reviews
k14 antibody - by Bioz Stars, 2026-03
85/100 stars
  Buy from Supplier

90
Jackson Laboratory k14-rtta mouse line
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
K14 Rtta Mouse Line, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k14-rtta mouse line/product/Jackson Laboratory
Average 90 stars, based on 1 article reviews
k14-rtta mouse line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Reichelt Chemietechnik keratin k14
Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) <t>K14</t> immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.
Keratin K14, supplied by Reichelt Chemietechnik, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/keratin k14/product/Reichelt Chemietechnik
Average 90 stars, based on 1 article reviews
keratin k14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of KRT14 and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.

Journal: Nature

Article Title: Blocking PGE 2 -induced tumour repopulation abrogates bladder cancer chemoresistance

doi: 10.1038/nature14034

Figure Lengend Snippet: a, Kaplan–Meier analysis of bladder-cancer patients with various CK14 staining patterns (enrich/pers denotes an enrichment (increase) or persistence of CK14 staining; resolution denotes an absence) after neoadjuvant chemotherapy (n = 15). b, Relative change in xenograft tumour size after chemotherapy (n = 6 xenograft tumours per group). PDX-3, patient-derived xenograft from patient 3; T24, human bladder cancer cell line-derived xenograft. c, d, Representative immunofluorescence staining (c) and box plots quantifying the percentage of CK14+ bladder cancer cells after chemotherapy (d). DAPI, 4′,6-diamidino-2-phenylindole. e, Schematic demonstrating the transduction of hK14.tdTomato lentiviral reporter into urothelial carcinoma cells. f, Immunofluorescence staining verifying the specific expression of tdTomato (Tm)-positive signal in CK14+ cancer cells. g, Quantitative PCR (qPCR) analysis of KRT14 and UPK1B in cancer cell subpopulations in biological duplicates. h, i, Graphs summarizing viability (h) and corresponding percentage of S phase cells (i) in two cancer subpopulations after chemotherapy in biological duplicates. j, Cell cycle profiles for Tm+ CK14+ (red line) and Tm− CK14− (black line) cancer cells at indicated days after chemotherapy. PI, propidium iodide. Data in b represent mean ± s.e.m.; box plots in c show twenty-fifth to seventy-fifth percentiles, with line indicating the median, and whiskers indicating the smallest and largest values; data in g–i show mean and range. ***P <0.001 (log-rank test (a) and two-tailed Student’s t-test (b)). Scale bars, 100 μm.

Article Snippet: We developed a lentiviral construct that reports on the activity of human KRT14 promoter by sub-cloning a previously characterized and validated promoter region of human KRT14 (ref. 16 ) (obtained from ATCC, MBA-124) using EcoRI and BamHI restriction enzymatic digestion, and inserting this promoter fragment into a promoterless lentiviral vector (Clontech, 631754) tagged with a DD-tdTomato (Tm) red fluorescent protein (Clontech Lenti-X DD-tdTomato vector).

Techniques: Staining, Derivative Assay, Immunofluorescence, Transduction, Expressing, Real-time Polymerase Chain Reaction, Two Tailed Test

Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) K14 immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.

Journal: Molecular therapy. Nucleic acids

Article Title: Mechanical stimuli-induced CCL2 restores adult mouse cells to regenerate hair follicles.

doi: 10.1016/j.omtn.2023.03.002

Figure Lengend Snippet: Figure 5. CCL2-CCR4 axis regulates plucking-induced hair regeneration (A) F4/80 immunostaining and statistics show recruitment of M1 macrophage at PPD3 after plucking. (B) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 after plucking. (C) TNF-a immunostaining and statistics show skin inflammation at PPD3 after plucking. (D) K14 immunostaining and statistics show hair regenerate at PPD3 after plucking. (E) K14 immunostaining and statistics show hair regeneration is blocked after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (F) F4/80 immunostaining and statistics show recruitment of M1 macrophage is disrupted after inhibition of CCL2 (iCCL2) or CCR4 (iCCR4) at PPD3. (G) CD206 immunostaining and statistics show no obvious recruitment of M2 macrophage at PPD3 in all three groups. (H) TNF-a immunostaining and statistics show significantly decreased skin inflammation after inhibition of iCCL2 or iCCR4 at PPD3. *p < 0.05, **p < 0.01, ***p < 0.001, #, no significance, n R 3.

Article Snippet: Primary antibodies include AE13 (ab16113, Abcam), AE15 (gift), CD34 (ab81289, Abcam), Sox9 (ab71762, Abcam), K10 (ab76318, Abcam), K14 (A01432, Boster), CD86 (ab53004, Abcam), F4-80 (sc-25830, Santa Cruz), CD163(sc-33560, Santa Cruz), CD206(sc58986, Santa Cruz), TNF-a (AF8208, Beyotime), NCAM (from Dr. Cheng-Ming Chuong laboratory), P16 (ab51243, Abcam), P63 (12143-1-AP, Proteintech), P-cadherin (13-2000Z, Thermo), and PCNA (ab92552, Abcam).

Techniques: Immunostaining, Inhibition